Orange Book product · Generic (ANDA)
CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE
At a glance
Apr 19, 2023
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Apr 19, 2023
3 yr 3 mo ago
Today
Pharmaceutical detail
Active ingredient
CISATRACURIUM BESYLATE
Strength
EQ 2MG BASE/ML
Dosage form
INJECTABLE
Route
INJECTION
TE code
AP
Application
ANDA 203079
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of CISATRACURIUM BESYLATE
- 1995NIMBEXBrand (NDA)
NDA 020551 · ABBVIE
- 2024CISATRACURIUM BESYLATE PRESERVATIVE FREEGeneric (ANDA)
ANDA 216539 · HAINAN POLY
- 2024CISATRACURIUM BESYLATEGeneric (ANDA)
ANDA 216538 · HAINAN POLY
- 2023CISATRACURIUM BESYLATEGeneric (ANDA)
ANDA 217725 · CAPLIN
- 2022CISATRACURIUM BESYLATEGeneric (ANDA)
ANDA 203078 · HIKMA
- 2022CISATRACURIUM BESYLATEGeneric (ANDA)
ANDA 215516 · GLAND
- 2022CISATRACURIUM BESYLATEGeneric (ANDA)
ANDA 212432 · PIRAMAL
- 2020CISATRACURIUM BESYLATEGeneric (ANDA)
ANDA 201836 · SAGENT PHARMS INC
- 2020CISATRACURIUM BESYLATEGeneric (ANDA)
ANDA 201851 · SAGENT PHARMS INC
- 2020CISATRACURIUM BESYLATE PRESERVATIVE FREEGeneric (ANDA)
ANDA 209665 · EUGIA PHARMA
- 2020CISATRACURIUM BESYLATEGeneric (ANDA)
ANDA 213527 · ZYDUS PHARMS
- 2020CISATRACURIUM BESYLATEGeneric (ANDA)
ANDA 209144 · EUGIA PHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
